PCOS affects more than 1 in 10 women worldwide, yet it remains one of the most under-diagnosed and under-treated conditions in women’s health. From irregular cycles and hormonal weight gain to mood instability and fertility struggles, the ripple effects of PCOS touch nearly every part of a woman’s life.
At BOND, our mission is simple: to give women daily tools that support their biology, not suppress it. This PCOS Awareness Month, we’re spotlighting the science behind one of the most promising, well-researched nutrients for women navigating PCOS-related challenges: inositol.
Clinically Studied Support for Women with PCOS
BOND’s Myo & D-Chiro Inositol blend delivers the same 40:1 ratio validated in clinical studies to support hormone balance and metabolic health.* This physiologically aligned ratio mirrors the body’s natural needs, offering targeted support for women experiencing PCOS-related symptoms.*
Clinical research has shown that inositol can help*:
-
Restore ovulation in up to 86% of women with PCOS
-
Support hormone balance by reactivating aromatase and reducing excess androgens
-
Improve insulin sensitivity and help reduce sugar cravings
-
Ease mood swings and emotional sensitivity tied to cycle phases
As highlighted in a recent review:
“Therapies based on inositols are usually well tolerated and can be extended over time without relevant side effects.”
— PMC: Intra-Ovarian Factors in PCOS, 2025
What Makes BOND Different
-
Clinically aligned 40:1 ratio of Myo & D-Chiro Inositol*
-
No added flavor, no added sugar — just pure, clean support*
-
Targets root-cause hormone dysfunction, not just surface symptoms*
-
Loved for mood, metabolism, cravings, and cycle support*
Unlike quick fixes, inositol works with your biology to help bring the body back into rhythm.*
Key Clinical Studies on Inositol
The science behind inositol supplementation is robust, with decades of research confirming its effectiveness in supporting metabolic, reproductive, and emotional health:
-
Gerli et al., 2007 (RCT): Myo-Inositol (4 g/day) reduced insulin, testosterone, and BMI in women with PCOS. → PubMed
-
Nordio & Proietti, 2012: The 40:1 Myo/DCI ratio outperformed Myo alone in restoring ovulation and improving metabolic markers. → PubMed
-
Palatnik et al., 2001: Myo-Inositol improved PMDD symptoms, including mood swings and irritability. → PubMed
-
Montanino Oliva et al., 2011 (Menopause Journal): In postmenopausal women, 4 g/day of Myo-Inositol improved insulin resistance, triglycerides, and blood pressure over 12 months. → Journal
-
Lentini et al., 2025 (Narrative Review): Myo supports estrogen production; DCI supports androgen modulation. The 40:1 ratio is physiologically grounded. → Dove Press
-
Gul et al., 2025 (RCT): Compared the 40:1 Inositol blend to metformin; both improved insulin sensitivity, cycle regularity, ovarian function, BMI, and quality of life. → PubMed
-
Zhang et al., 2025 (Meta-analysis): Myo-Inositol improved egg quality, MII rate, and fertilization success in IVF patients. → Frontiers
The Bottom Line
PCOS isn’t “just irregular cycles” — it’s a complex, full-body condition with ripple effects on energy, mood, fertility, and long-term metabolic health. The good news? Research is catching up, and women have more options than ever.
This PCOS Awareness Month, BOND is committed to shining a light on science-backed tools like inositol that help women feel more in sync with their bodies.* Because every woman deserves to feel supported — not dismissed.
Works Cited
-
Gerli, S., et al. (2007). “Myo-Inositol in patients with polycystic ovary syndrome: a randomized, controlled trial.” PubMed. https://pubmed.ncbi.nlm.nih.gov/17389902
-
Nordio, M., & Proietti, E. (2012). “The 40:1 Myo-Inositol/DCI ratio: clinical advantages.” PubMed. https://pubmed.ncbi.nlm.nih.gov/23247292
-
Palatnik, A., et al. (2001). “Myo-Inositol in PMDD symptom management.” PubMed. https://pubmed.ncbi.nlm.nih.gov/11386498
-
Montanino Oliva, M., et al. (2011). “Effects of Myo-Inositol supplementation in postmenopausal women.” Menopause Journal. https://journals.lww.com/menopausejournal/abstract/2011/01000/effects_of_myo_inositol_supplementation_in.20.aspx
-
Lentini, M., et al. (2025). “PCOS and Inositols: Advances and lessons we are learning.” Drug Design, Development and Therapy. https://www.dovepress.com/pcos-and-inositols–advances-and-lessons-we-are-learning-a-narrative-r-peer-reviewed-fulltext-article-DDDT
-
Gul, H., et al. (2025). “Myo/DCI 40:1 vs. Metformin in PCOS.” PubMed. https://pubmed.ncbi.nlm.nih.gov/39847053
-
Zhang, Y., et al. (2025). “Myo-Inositol and egg quality in IVF: A meta-analysis.” Frontiers in Endocrinology. https://www.frontiersin.org/articles/10.3389/fendo.2025.1520362/full